Dr. Yubin Kang received his medical degree from the Shanghai Second Military Medical University in China. Dr. Kang is a professor of medicine and a board-certified practicing hematologist/oncologist and hematopoietic stem cell transplant physician at Duke University. Dr. Kang's research interests focus on plasma cell dyscrasia and hematopoietic stem cell biology. Dr. Kang has led several investigator-initiated trials and pharmaceutical company-sponsored studies. He has authored and co-authored numerous investigations on new target therapies in myeloma, immunotherapy, and novel approaches for hematopoietic stem cell transplantation. He has won several prestigious national research awards. Dr. Kang has been invited to serve on national and international study and review panels, including the NCCN multiple myeloma, systemic light chain amyloidosis, and Waldenstrom macroglobulinemia guidelines panel, NIH study sections, and the International Myeloma Foundation Brian D. Dovis Research Grant.
Dr. Yubin Kang received his medical degree from the Shanghai Second Military Medical University in China. Dr. Kang is a professor of medicine and a board-certified practicing hematologist/oncologist and hematopoietic stem cell transplant physician at Duke University. Dr. Kang's research interests focus on plasma cell dyscrasia and hematopoietic stem cell biology. Dr. Kang has led several investigator-initiated trials and pharmaceutical company-sponsored studies. He has authored and co-authored numerous investigations on new target therapies in myeloma, immunotherapy, and novel approaches for hematopoietic stem cell transplantation. He has won several prestigious national research awards. Dr. Kang has been invited to serve on national and international study and review panels, including the NCCN multiple myeloma, systemic light chain amyloidosis, and Waldenstrom macroglobulinemia guidelines panel, NIH study sections, and the International Myeloma Foundation Brian D. Dovis Research Grant.